De-intensification of basal-bolus insulin regimen after initiation of a GLP-1 RA improves glycaemic control and promotes weight loss in subjects with type 2 diabetes

被引：0
|
作者：
Pierpaolo Falcetta
Francesca Nicolì
Fabrizia Citro
Annamaria Ciccarone
Monia Garofolo
Stefano Del Prato
Cristina Bianchi
机构：
[1] University of Pisa,Department of Clinical and Experimental Medicine
[2] University Hospital of Pisa,Department of Medicine
来源：
Acta Diabetologica | 2023年 / 60卷
关键词：
Insulin therapy; Basal-bolus; Glucagon-like peptide-1 receptor agonist; De-intensification;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：53 / 60
页数：7
相关论文
共 50 条
  • [31] Introduction of insulin glargine to basal-bolus therapy improves metabolic control in patients with type 1 diabetes in everyday clinical practice
    Donaubauer, B
    Schneider, K
    Schweitzer, MA
    DIABETOLOGIA, 2005, 48 : A329 - A329
  • [32] Glycaemic control and weight outcomes after adding or switching to biphasic insulin aspart 30/70 in people with type 2 diabetes mellitus previously treated with basal-bolus insulin in UK clinical practice
    Davies, Melanie J.
    Alibegovic, Amra Ciric
    Kelkar, Pranav
    Braae, Uffe Christian
    Jensen, Anders Boeck
    DIABETES OBESITY & METABOLISM, 2023, 25 (12): : 3841 - 3844
  • [33] Introduction of insulin glargine to basal-bolus therapy improves metabolic control in patients with type 2 diabetes in everyday clinical practice
    Ruhnau, KJ
    Schneider, K
    Schweitzer, MA
    DIABETES, 2005, 54 : A518 - A518
  • [34] Introduction of insulin glargine to basal-bolus therapy improves metabolic control in patients with type 2 diabetes in everyday clinical practice
    Ruhnau, KJ
    Schneider, K
    Schweitzer, MA
    DIABETOLOGIA, 2005, 48 : A303 - A303
  • [35] Eating Behavior Is Associated with Long-term Weight Loss Following GLP-1 RA Treatment in Type 2 Diabetes on Insulin
    De Boer, Stefanie A.
    Mulder, Douwe J.
    Lefrandt, Joop D.
    Hoogenberg, Klaas
    DIABETES, 2014, 63 : A248 - A248
  • [36] Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy
    Hirsch, I. B.
    Buse, J. B.
    Leahy, J.
    McGill, J. B.
    Peters, A.
    Rodbard, H. W.
    Rubin, R. R.
    Skyler, J. S.
    Verderese, C. A.
    Riddle, M. C.
    DIABETES OBESITY & METABOLISM, 2014, 16 (03): : 206 - 214
  • [37] Switching from basal-bolus therapy with NPH insulin to basal-bolus therapy with the analog insulin detemir improves glycemic control and reduces hypoglycemic episodes, without weight gain, in type 1 and type 2 diabetes patients: Results from German subgroup of the PREDICTIVE study
    Ruhnau, Klaus-Juergen
    Hansen, Jes B.
    Dornhorst, Anne
    DIABETES, 2006, 55 : A133 - A133
  • [38] Empagliflozin as add-on to basal insulin for 78 weeks improves glycaemic control with weight loss in insulin-treated type 2 diabetes mellitus
    Rosenstock, J.
    Jelaska, A.
    Wang, F.
    Kim, G.
    Broedl, U. C.
    Woerle, H. J.
    DIABETOLOGIA, 2013, 56 : S372 - S372
  • [39] GLP1-RA Add-on Therapy in Patients with Type 2 Diabetes Currently on a Bolus Containing Insulin Regimen
    Davies, Marie L.
    Pham, David Q.
    Drab, Scott R.
    PHARMACOTHERAPY, 2016, 36 (08): : 893 - 905
  • [40] Insulin dose and weight profiles of pre- and post-meal insulin glutisine (GLU) in a basal-bolus regimen with insulin glargine in patients with type 1 diabetes
    Garg, S
    Rosenstock, J
    Ways, K
    DIABETES, 2004, 53 : A125 - A126
12345